Capsida Biotherapeutics

Capsida Biotherapeutics is a private, clinical-stage biotech company pioneering a novel approach to gene therapy through its proprietary AAV capsid engineering platform. Founded in 2019 and based in Thousand Oaks, California, the company is developing targeted, IV-administered therapies designed to deliver genetic cargo specifically to diseased tissues while minimizing off-target effects. With a fully integrated model spanning discovery through GMP manufacturing, Capsida is advancing a pipeline led by programs for STXBP1-DEE and PD-GBA, backed by strategic collaborations with AbbVie, CRISPR Therapeutics, and Lilly. The company is financed by leading venture firms and faces the inherent risks of clinical development, including recent serious adverse events in its lead program.

Proprietary engineered AAV capsid platform featuring high-throughput, in vivo screening in non-human primates to create vectors with targeted tissue delivery and reduced off-target tropism.

Capsida competes with other gene therapy companies developing AAV-based treatments for neurological diseases (e.g., Neurocrine, Lysogene, Prevail/AbbVie) and a new wave of companies engineering capsids (e.g., Dyno Therapeutics, 4D Molecular Therapeutics). Its key differentiation is its integrated platform and focus on systemic, targeted delivery to the CNS. It also faces competition from non-viral modalities like RNA therapies and small molecules for conditions like Parkinson's.